Kaposi sarcoma-associated herpes virus and response to antiretroviral therapy: A prospective study of HIV-infected adults

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 4, 2013, Pages 442-448

  Maskew, Mhairi ^a   Macphail, A Patrick ^a   Whitby, Denise ^b   Egger, Matthias ^c   Fox, Matthew P ^a,d  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiretroviral therapy; Kaposi sarcoma herpes virus; Resource poor setting; Virologic suppression

Indexed keywords

HEMOGLOBIN;

ADULT; AFRICA; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SOUTH AFRICA; TREATMENT DURATION; TUBERCULOSIS; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIGENS, NUCLEAR; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; GLYCOPROTEINS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VIRAL LOAD; VIRAL PROTEINS;

EID: 84880227939     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182969cc1     Document Type: Article

References (42)

1. Klaskala W, Brayfield BP, Kankasa C, et al. Epidemiological characteristics of human herpesvirus-8 infection in a large population of antenatal women in Zambia. J Med Virol. 2005;75:93-100.
2. Adjei A, Armah HB, Gbagbo F, et al. Seroprevalence of HHV-8, CMV, and EBV among the general population in Ghana, West Africa. BMC Infect Dis. 2008;8:111.
3. Malope-Kgokong BI, Macphail P, Mbisa G, et al. Kaposi?s sarcoma associated-herpesvirus (KSHV) seroprevalence in pregnant women in South Africa. Infect Agent Cancer. 2010;5:14.
4. UNAIDS. Global Report. UNAIDS Report on the Global AIDS Epidemic. Joint United Nations Programme on HIV/AIDS (UNAIDS). Geneva, Switzerland:Joint United Nations Programme on HIV/AIDS. 2010.
5. Sarid R, Olsen SJ, Moore PS. Kaposi sarcoma-associated herpesvirus:epidemiology, virology, and molecular biology. Adv Virus Res. 1999;5:2139-2232.
6. Sitas F, Carrara H, Beral V, et al. Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med. 1999;340:1863-1871.
7. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi sarcoma. Lancet. 1995;346:799-802.
8. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86:1276-1280.
9. Cesarman E, Chang Y, Moore PS, et al. Kaposi sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332:1186-1191.
10. Boshoff C, Weiss R. AIDS-related malignancies. Nat Rev Cancer. 2002; 2:373-382.
11. Covacs A, Schluchter M, Easley K, et al. Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. New Engl J Med. 1999;341:77-84.
12. Greub B, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection:The Swiss HIV Cohort Study. Lancet. 2000;356:1800-1805.
13. Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS. 2004;18:1169-1177.
14. Mercader M, Taddeo B, Panella J.R. et al. Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells. Am J Pathol. 2000;156:1961-1971.
15. Mercader M, Nickoloff BJ, Foreman KE. Induction of human immunodeficiency virus 1 replication by human herpesvirus
16. Arch Pathol Lab Med. 2001;125:785-789.
17. Caselli E, Galvan M, Cassai E, et al. Human herpesvirus 8 enhances human immunodeficiency virus replication in acutely infected cells and induces reactivation in latently infected cells. Blood. 2005;106:2790-2797.
18. Fox MP, Maskew M, Macphail AP, et al. Cohort profile:The Themba Lethu clinical cohort, Johannesburg, South Africa. Int J Epidemiol. 2012 doi:10.1093/ije/dys029.
19. South African National Ministry of Health. National Antiretroviral Treatment Guidelines. 1st ed. Pretoria, South Africa:National Department of Health Republic of South Africa; 2004.
20. South African National Ministry of Health. The South African Antiretroviral Treatment Guidelines. Pretoria, South Africa:National Department of Health Republic of South Africa; 2010.
21. Fox MP, Brennan A, Maskew M, et al. Using vital registration data to update mortality among patients lost to follow-up from ART programmes:evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health. 2010;15:405-413.
22. Egger M, Ekouevi DK, Williams C, et al. Cohort Profile:The international epidemiological databases to evaluate AIDS (IeDEA) in sub- Saharan Africa. Int J Epidemiol. 2012;41:1256-1264.
23. Mbisa GL, Miley W, Gamache CJ, et al. Detection of antibodies to Kaposi sarcoma associated herpesvirus: A new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA. J Immunol Methods. 2010;356:39-46.
24. de Sanjosé S, Marshall V, Solà J, et al. Prevalence of Kaposi sarcomaassociated herpesvirus infection in sex workers and women from the general population in Spain. Int J Cancer. 2002;98:155-158.
25. Maskew M, MacPhail AP, Whitby D, et al. Prevalence and predictors of Kaposi sarcoma herpesvirus seropositivity: A cross-ectional analysis of HIV-infected adults initiating ART in Johannesburg, South Africa. Infect Agents Cancer. 2011;6:22.
26. Wilkinson J, Cope A, Gill J, et al. Identification of Kaposi sarcomaassociated herpesvirus (KSHV)-pecific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-pecific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. J Virol. 2002;76:2634-2640.
27. Aoki Y, Tosato G. HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. Blood. 2004;104:810-814.
28. Lukac DM, Kirshner J.R. Ganem D. Transcriptional activation by the product of open reading frame 50 of Kaposi sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells. J Virol. 1999;73:9348-9361.
29. Adang LA, Parsons C.H. Kedes DH. Asynchronous progression through the lytic cascade and variations in intracellular viral loads revealed by high-throughput single-cell analysis of Kaposi sarcoma-associated herpesvirus infection. J Virol. 2006;80:10073-10082.
30. Taylor MM, Chohan B, Lavreys L, et al. Shedding of human herpesvirus 8 in oral and genital secretions from HIV-1-eropositive and -eronegative Kenyan women. J Infect Dis. 2004;190:484-488.
31. Chêne G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy, analysis of prospective studies. Lancet. 2003;362:679-686.
32. CarrieriMP, Raffi F, Lewden C, et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virologic response, a 3-year follow-up study. Antivir Ther. 2003;8:585-594.
33. Lawn S, Harries A, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-aharan Africa. AIDS. 2008;22:1897-1908.
34. Boshoff C, Endo Y, Collins PD, et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science. 1997;278:290-294.
35. Lusso P. Chemokines and viruses:The dearest enemies. Virology. 2000; 273:228-240.
36. Ait-Arkoub Z, Robert-Visse C, Calvez V, et al. No influence of human herpesvirus 8 infection on the progression of HIV-1 infection in initially asymptomatic patients. AIDS. 2003;17:1394-1396.
37. Aversa SML, Cattelan AM, Salvagno L, et al. Treatments of AIDSrelated Kaposi sarcoma. Crit Rev Oncol/Hematol. 2005;53:253-265.
38. Gill J, Bourboulia D, Wilkinson J, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr. 2002;31:384-390.
39. Bourboulia D, Aldam D, Lagos D, et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS. 2004;18:485-493.
40. Malope BI, MacPhail P, Mbisa G, et al. No evidence of sexual transmission of Kaposi sarcoma herpesvirus in a heterosexual South African population. AIDS. 2008;22:519-526.
41. Smith N, Sabin C, Gopal R, et al. Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex. J Infect Dis. 1999;180:600-606.
42. Mbulaiteye SM, Biggar RJ, Pfeiffer RM, et al. Water, socioeconomic factors, and human herpesvirus 8 infection in Ugandan children and their mothers. J Acquir Immune Defic Syndr. 2005;38:474-479.